



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/63202	SERIAL NO. 10/781,543
	APPLICANT FLASHNER-BARAK et al.	
	FILING DATE February 17, 2004	GROUP 1614

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 96/40192	December 19, 1996	PCT				
	WO 03/082247	October 9, 2003	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	S. Nazzal et al., "Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation", Int. J. of Pharmaceutics (Kidlington), Vol. 235, No. 1-2, Pages 247-265, (2002)
	P. W. Stott et al., "Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen", J. of Controlled Release, Vol. 50, No. 1-3, pages 297-308, (1998)
	L. Kang et al., "Physicochemical studies of lidocaine-menthol binary systems for enhanced membrane transport", Int. J. of Pharmaceutics (Kidlington), Vol. 206, No. 1-2, Pages 35-42, (2000)
	Y. Kaplun-Frischoff et al., "Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids", J. of Pharmaceutical Sciences, Vol. 86, No. 12, Pgs. 1394-1399, (1997)

EXAMINER /Leslie Royds/ (06/03/2008)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LR/ (06/03/2008)